Moderna (MRNA) shares rallied sharply on Tuesday, climbing nearly 10% to $57.19, as investors reacted to a favorable review from U.S. Food and Drug Administration staff regarding the company's mRNA-based seasonal influenza vaccine, mFlusiva. The stock's advance stood out against a backdrop of broader market weakness, with the SPDR S&P 500 ETF Trust (SPY) slipping 0.4% and the Invesco QQQ Trust (QQQ) falling 1.4%.
The FDA staff review, published ahead of a key advisory committee meeting scheduled for June 18, indicated that immune-response data from Moderna's clinical trial "may support effectiveness" of mFlusiva in adults aged 65 and older. This assessment was seen by analysts as a significant reduction in regulatory risk for Moderna's push to expand its mRNA platform beyond COVID-19 vaccines. The company is seeking full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, the latter of which can rely on immune-response biomarkers but requires confirmatory data later.
According to a Reuters report, the FDA briefing documents also highlighted that Moderna's vaccine, mRNA-1010, demonstrated a 26.6% relative vaccine efficacy (rVE) against RT-PCR-confirmed influenza-like illness compared to a standard-dose flu shot in adults over 50. rVE measures how much better one vaccine performs versus another in a head-to-head trial. However, the FDA noted limitations, including that the data came from a single flu season and did not include immunocompromised or very frail older adults, leaving some uncertainty about efficacy in high-risk populations.
The advisory committee vote on June 18 will assess the benefit-risk profile of mFlusiva. While the panel's recommendation is non-binding, it is a critical milestone for Moderna. The FDA is expected to make its final decision by August 5. Jefferies analyst Andrew Tsai described the FDA review as favorable and projects $750 million in U.S. sales from Moderna's flu and combined COVID-flu vaccines by 2030.
Moderna's stock move comes amid a series of strategic developments. The company announced new leadership appointments, including Ester Banque as chief commercial officer and increased oversight by President Stephen Hoge over infectious disease, intismeran, and rare disease portfolios. These moves signal preparations for potential product launches in 2027 and 2028, including a combined flu-COVID vaccine, a standalone seasonal flu vaccine, and a norovirus vaccine. Moderna is also awaiting clinical milestones for intismeran and propionic acidemia treatments.
Despite the positive sentiment, bearish arguments remain. The FDA briefing noted higher rates of reported adverse reactions for mFlusiva compared to other vaccines, although serious adverse events were roughly balanced. Biotech stocks are highly sensitive to regulatory events, as a single decision can dramatically alter future revenue expectations. Moderna's financial position remains under pressure: first-quarter revenue was $389 million, with a net loss of $1.3 billion, or $3.40 per share. Cash, cash equivalents, and investments totaled $7.5 billion as of March 31. The company targets up to 10% revenue growth in 2026 but expects year-end cash and investments to fall to $4.5 billion-$5.0 billion.
With negative earnings per share, traditional valuation metrics like price-to-earnings ratio are not applicable. Investors are betting on regulatory approvals, successful product launches, and cost discipline. The risk is clear: a negative advisory panel outcome, a narrower label, or weaker-than-expected vaccine demand could quickly erase recent gains. The June 18 vote is the next major catalyst for Moderna shares.
